Covaxin Covid Vaccine
-
{
- All
- News
- Videos
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
- Thursday May 16, 2024
- India News | Indo-Asian News Service
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
www.ndtv.com
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
- Thursday May 16, 2024
- India News | Press Trust of India
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
www.ndtv.com
-
Japan Recognises Covaxin In Move To Facilitate Travel With India From Sunday
- Friday April 8, 2022
- India News | Press Trust of India
Japan has included Bharat Biotech's Covaxin in the list of recognised vaccines, a move aimed at facilitating travel between the two countries.
-
www.ndtv.com
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
- Thursday January 27, 2022
- India News | Reported by Parimal Kumar, Edited by Debanish Achom
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
www.ndtv.com
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
- Thursday January 27, 2022
- India News | Press Trust of India
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
www.ndtv.com
-
Monthly Production Of Covishield, Covaxin Planned To Be Increased: Centre
- Friday August 6, 2021
- India News | Press Trust of India
The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.
-
www.ndtv.com
-
Delhi Gets Over 60,000 Covaxin Doses For Those Over 45: AAP's Atishi
- Tuesday May 18, 2021
- Delhi News | Edited by Ashutosh Tripathi
Delhi received over 60,000 Covaxin doses for those above 45 years, Aam Aadmi Party MLA Atishi said Tuesday, adding that the city still has only two days of Covaxin stock for this age group.
-
www.ndtv.com
-
India To Review Vaccine Side Effects Amid Blood Clot Concerns: Report
- Friday April 9, 2021
- India News | Reuters
A government panel of experts is investigating for any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, financial daily Mint reported on Friday.
-
www.ndtv.com
-
Haryana Health Minister Anil Vij Explains Why He Won't Take Covid Vaccine
- Monday March 1, 2021
- India News | Edited by Deepshikha Ghosh
As the second phase of the nationwide Covid vaccination began with Prime Minister Narendra Modi as the first beneficiary, Haryana Health Minister Anil Vij tweeted that he did not need the vaccine.
-
www.ndtv.com
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
- Thursday May 16, 2024
- India News | Indo-Asian News Service
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
www.ndtv.com
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
- Thursday May 16, 2024
- India News | Press Trust of India
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
www.ndtv.com
-
Japan Recognises Covaxin In Move To Facilitate Travel With India From Sunday
- Friday April 8, 2022
- India News | Press Trust of India
Japan has included Bharat Biotech's Covaxin in the list of recognised vaccines, a move aimed at facilitating travel between the two countries.
-
www.ndtv.com
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
- Thursday January 27, 2022
- India News | Reported by Parimal Kumar, Edited by Debanish Achom
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
www.ndtv.com
-
Covid Vaccines Covishield, Covaxin Get Conditional Market Approval: Report
- Thursday January 27, 2022
- India News | Press Trust of India
India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.
-
www.ndtv.com
-
Monthly Production Of Covishield, Covaxin Planned To Be Increased: Centre
- Friday August 6, 2021
- India News | Press Trust of India
The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.
-
www.ndtv.com
-
Delhi Gets Over 60,000 Covaxin Doses For Those Over 45: AAP's Atishi
- Tuesday May 18, 2021
- Delhi News | Edited by Ashutosh Tripathi
Delhi received over 60,000 Covaxin doses for those above 45 years, Aam Aadmi Party MLA Atishi said Tuesday, adding that the city still has only two days of Covaxin stock for this age group.
-
www.ndtv.com
-
India To Review Vaccine Side Effects Amid Blood Clot Concerns: Report
- Friday April 9, 2021
- India News | Reuters
A government panel of experts is investigating for any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, financial daily Mint reported on Friday.
-
www.ndtv.com
-
Haryana Health Minister Anil Vij Explains Why He Won't Take Covid Vaccine
- Monday March 1, 2021
- India News | Edited by Deepshikha Ghosh
As the second phase of the nationwide Covid vaccination began with Prime Minister Narendra Modi as the first beneficiary, Haryana Health Minister Anil Vij tweeted that he did not need the vaccine.
-
www.ndtv.com